Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06529991

Self-Myofascial Release of the Upper Cervical Muscles

Exploring the Effect of Self-Myofascial Release of the Upper Cervical Muscles on the Superficial Back Fascial Train

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Edward Via Virginia College of Osteopathic Medicine · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Accepted

Summary

The primary objective is to examine the influence of the suboccipital muscles on the superficial back line. The investigators will measure the following as part of this objective: * Changes in biomechanical and viscoelastic properties of points within the superficial back fascial train measured by a handheld myotonometer. * Pain pressure threshold measured by algometry. * Ankle range of motion. * Foot plantar pressure changes. All participants will have a 5-minute self-myofascial release intervention.

Detailed description

The superficial back line is a network myofascial segments that are connected and extend from the plantar foot up through the posterior lower extremity and back, up to the head. These connective tissue and muscular tracks play a role in supporting upright stance and motion. Dysfunction in one segment of the superficial back line can manifest as pain in a different segment of the fascial system. For example, hamstring and gastrocnemius muscle tightness have been associated with altered foot biomechanics and pain. The suboccipital muscles play an important role in head and body posture; therefore, they can influence eye positioning as it relates to head movements and perturbations. Because of this, the suboccipital muscles may have a hierarchical control over the SBFL. Dysfunction in the suboccipital muscles may exert more widespread effects on muscles and tissues at distant regions of the SBFL. Studies have shown that neck pain and forward head posture are associated with altered gait and ankle posture respectively. In addition, stress, anxiety, and poor sleep quality are associated with increased pain sensitivity and disability. How the interconnectedness of the SBFL responds to treatment is not fully understood. Proper treatment of musculoskeletal pain requires a better understanding of the function of myofascial connections and how dysfunction in one segment affects other regions. Also, enhanced understanding of the influence of stress, anxiety, and low sleep quality on response to treatment is needed. This understanding will better inform clinical practice and support the need for a more holistic approach to treating musculoskeletal pain. The primary objective is to examine the influence of the suboccipital muscles on the superficial back line. Specifically, investigators will measure the following as part of this objective: * Changes in biomechanical and viscoelastic properties of points within the superficial back fascial train measured by a handheld myotonometer. * Pain pressure threshold measured by algometry. * Ankle range of motion. * Foot plantar pressure changes. A secondary objective is to demonstrate a relationship between changes within the SBFL and stress, anxiety, sleep quality and non-debilitating pain. To achieve this secondary objective, the investigators will use the following: * Perceived Stress Scale-10 (PSS-10) * General Anxiety Disorder-7 (GAD-7) * Pittsburgh Sleep Quality Index (PSQI) * Numerical Rating Scale (NRS) will be utilized to record participants' intensity, frequency, and duration of non-debilitating lower extremity pain and back pain.

Conditions

Interventions

TypeNameDescription
DEVICEOccipivot suboccipital pillow self-myofascial releaseSubjects will be instructed in the use of the Occipivot suboccipital pillow and how "it should feel." They will be supervised as it is placed. Once verbal verification is obtained regarding the feel and placement of the wedge, the treatment time will begin and continue for 5 minutes.

Timeline

Start date
2024-06-26
Primary completion
2025-10-01
Completion
2026-04-26
First posted
2024-07-31
Last updated
2025-08-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06529991. Inclusion in this directory is not an endorsement.